| Title |
Comparison of acid inhibition with standard dosages of proton pump inhibitors in relation to CYP2C19 genotype in Japanese
|
|---|---|
| Published in |
European Journal of Clinical Pharmacology, July 2014
|
| DOI | 10.1007/s00228-014-1713-y |
| Pubmed ID | |
| Authors |
Mitsushige Sugimoto, Naohito Shirai, Masafumi Nishino, Chise Kodaira, Takahiro Uotani, Shu Sahara, Hitomi Ichikawa, Takuma Kagami, Ken Sugimoto, Takahisa Furuta |
| Abstract |
The aim of therapeutic regimens using proton pump inhibitors (PPIs) in patients with acid-related diseases is to potently inhibit acid secretion for the full 24 h. However, optimum treatment is still unclear because the pharmacodynamics of PPIs differ among CYP2C19 genotypes and most of the previous studies have had loss of sample power. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 22 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 22 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 5 | 23% |
| Student > Bachelor | 3 | 14% |
| Other | 2 | 9% |
| Student > Ph. D. Student | 2 | 9% |
| Lecturer | 1 | 5% |
| Other | 2 | 9% |
| Unknown | 7 | 32% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 8 | 36% |
| Pharmacology, Toxicology and Pharmaceutical Science | 4 | 18% |
| Biochemistry, Genetics and Molecular Biology | 1 | 5% |
| Sports and Recreations | 1 | 5% |
| Agricultural and Biological Sciences | 1 | 5% |
| Other | 0 | 0% |
| Unknown | 7 | 32% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 15 July 2014.
All research outputs
#19,280,634
of 23,866,543 outputs
Outputs from European Journal of Clinical Pharmacology
#2,274
of 2,623 outputs
Outputs of similar age
#166,745
of 229,889 outputs
Outputs of similar age from European Journal of Clinical Pharmacology
#13
of 19 outputs
Altmetric has tracked 23,866,543 research outputs across all sources so far. This one is in the 10th percentile – i.e., 10% of other outputs scored the same or lower than it.
So far Altmetric has tracked 2,623 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.2. This one is in the 6th percentile – i.e., 6% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 229,889 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 14th percentile – i.e., 14% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 19 others from the same source and published within six weeks on either side of this one. This one is in the 15th percentile – i.e., 15% of its contemporaries scored the same or lower than it.